Sphere Fluidics, Cambridge, UK, a company commercializing single-cell analysis systems underpinned by its patented picodroplet technology, has introduced the Cyto-Mine studio software suite, an updated software solution for its innovative Cyto-Mine single-cell analysis system. The software works alongside industry-standard robotic platforms and corporate databases to improve antibody discovery and cell line development workflows.
Rob Marchmont, PhD, Sphere Fluidics.
Cyto-Mine is an automated platform that integrates single-cell screening, sorting, isolation, and clone verification. The Cyto-Mine studio software suite has updated features and user interfaces for Cyto-Mine instrument control software and offline Cyto-Mine data analysis software. It also has an application programming interface that enables easy communication with many industry-standard robotic platforms and links to corporate databases for easy data transfer. The suite includes features such as single-cell dispensing to individual wells of 96- and 384-well microtiter plates and software data outputs from single-cell imaging analysis.
“Developed with feedback from Sphere Fluidics’ customers, the new software has user-friendly and intuitive navigation, is secure, and has programming features to allow scientists to easily monitor and run industry-standard workflows to find new rare antibody-producing cells and high-expressing cells from CHO cell lines or transfection pools,” says Rob Marchmont, PhD, director of sales and marketing at Sphere Fluidics. “We are now updating our installed systems in Asia, Europe, and the United States, with favorable customer feedback.”
Marian Rehak, PhD, Sphere Fluidics.
“The new software is robust and brings updated features to the Cyto-Mine platform, providing high-throughput single-cell analysis and monoclonality assurance for antibody discovery and cell line development,” adds Marian Rehak, PhD, director of research and development at Sphere Fluidics. “Cyto-Mine can process small numbers of cells (eg, a hundred thousand) for monoclonality assurance through to 40 million cells for high-throughput antibody discovery. Inclusion of single-cell imaging at various check points and data outputs is particularly powerful for monoclonality assurance.”
To learn more, visit Sphere Fluidics.
